Black currant anthocyanins normalized abnormal levels of serum concentrations of endothelin-1 in patients with glaucoma.
Black currant anthocyanins normalized abnormal levels of serum concentrations of endothelin-1 in patients with glaucoma.
复制标题
DOI：
10.1089/jop.2012.0198
复制
发表时间：
2013-05
期刊：
影响因子：
--
通讯作者：
Kaori Yoshida;Ikuyo Ohguro;H. Ohguro
中科院分区：
文献类型：
--
作者：
Kaori Yoshida;Ikuyo Ohguro;H. Ohguro
我们最近的一项研究涉及一项随机、安慰剂对照、双盲、为期24个月的试验（Ophthalmologica 2012;228：26-35），该研究显示，口服黑加仑花青素（BCACs）可减缓开角型青光眼（OAG）的视野恶化和眼血流量升高。为了阐明这些BCAC诱导的作用的潜在机制，作为可能的影响青光眼视神经病变的因素，在本研究中，检测了血清内皮素-1（ET-1）、一氧化氮（NO）和抗氧化活性的变化。方法在OAG患者中，随机、安慰剂对照、双盲试验，在基线和每6个月从BCAC治疗（n=19）或安慰剂治疗（n=19）的患者中获得血清标本。健康志愿者（n=20）与患者的年龄和性别匹配作为对照。用市售试剂盒测定血清ET-1浓度、[NO2（-）]和[NO2（-）+ NO3（-）]水平、晚期氧化蛋白产物（AOPP）和抗氧化活性。结果OAG患者血清ET-1浓度（BCACs组3.18±1.06 pg/mL，安慰剂组3.44±0.84 pg/mL）显著低于健康志愿者（4.38±1.03 pg/mL）（单因素方差分析和Tukey多重比较事后检验，P<0.05）。BCACs给药后，血清ET-1浓度在24个月期间增加到健康志愿者的水平。相比之下，安慰剂治疗患者的这些水平保持在较低水平（3.82±1.14 pg/mL）。虽然BCAC组和安慰剂组患者的[NO2（-）]和[NO2（-）+NO3（-）]水平、AOPP和抗氧化活性在基线时与健康受试者的水平相当，但在观察期间，BCAC组或安慰剂组均未观察到显著变化。结论：在BCACs对OAG患者视野进展的可能有益作用中，我们目前的结果表明，BCACs引起血清ET-1水平正常化，这可能调节ET-1依赖的眼部血液动力学调节。
PURPOSE Our recent study, which involved a randomized, placebo-controlled, double-masked 24-month trial (Ophthalmologica 2012;228:26-35), revealed that oral administration of black currant anthocyanins (BCACs) slowed down the visual field deterioration and elevation of ocular blood flow of open-angle glaucoma (OAG). To elucidate the underlying mechanisms of these BCAC-induced effects, as possible factors affecting glaucomatous optic neuropathy, changes of serum endothelin-1 (ET-1), nitric oxide (NO), and antioxidative activities were examined in the present study. METHODS From among patients with OAG who participated in the randomized, placebo-controlled, double-masked trial, serum specimens were obtained from BCAC-treated (n=19) or placebo-treated (n=19) patients at baseline and every 6 months. Healthy volunteers (n=20) with age and gender matching the patients were used as a control. Serum ET-1 concentration, [NO2(-)] and [NO2(-) + NO3(-)] levels, advanced oxidation protein products (AOPP), and antioxidant activities were measured by using commercially available kits. RESULTS At the trial baseline, serum ET-1 concentrations were significantly lower in patients with OAG (BCACs, 3.18±1.06 pg/mL; placebo, 3.44±0.84 pg/mL) than those in healthy volunteers (4.38±1.03 pg/mL) (one-way analysis of variance and a Tukey's multiple comparison post hoc test, P<0.05). Upon administration of BCACs, serum ET-1 concentrations increased to the levels of those in healthy volunteers during the 24-month period. In contrast, those of placebo-treated patients remained at lower levels (3.82±1.14 pg/mL). While [NO2(-)] and [NO2(-)+NO3(-)] levels, AOPP, and antioxidative activities of patients from both the BCACs and placebo groups showed comparable levels to those of healthy subjects at baseline, no significant changes were observed during the observational period in either the BCAC or placebo groups. CONCLUSIONS Among the possible beneficial effects of BCACs toward visual field progression in patients with OAG, our present results suggest that BCACs caused normalization of serum ET-1 levels, and this may modulate ET-1-dependent regulation of the ocular blood hemodynamics.